Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.58 +0.17 (+0.18%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
52 53 Next >
Expert Ratings for Gilead Sciences
Analysts have provided the following ratings for Gilead Sciences (NASDAQ:GILD) within the last quarter: 
Via Benzinga
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Gilead Sciences, Inc.
Via Business Wire
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a... 
Via MarketBeat
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
From Gilead Sciences, Inc.
Via Business Wire
Why NuCana Shares Are Rising Today?
Via Benzinga
HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock
Via Benzinga
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period 
Via SBWire
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
Recent Stock Purchase June 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. 
Via Talk Markets
Q2 Earnings: Energy and What Else?
S&P 500 earnings are expected to be up 2.5% year-over-year on 10.8% higher revenues. But much of that is attributed to energy, which is expected to have another record quarter. 
Via Talk Markets
AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
$1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.74% on an annualized basis producing an average annual return of 8.04%. Currently, Gilead Sciences has a market... 
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues
Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the... 
Via Benzinga
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
More than four in 10 people in a recent survey knew of someone with long Covid. 
Via Investor's Business Daily
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
From Gilead Sciences, Inc.
Via Business Wire
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Traders See Bumpy Road Ahead For Gilead Sciences
Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses. 
Via Benzinga
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
From Gilead Sciences, Inc.
Via Business Wire
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic. 
Via Benzinga
Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions
Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture... 
Via Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
Via Benzinga
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.